9:00am - 5:00pm

Office Hours Mon. - Fri.


Call Us For Free Consultation




Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study

Estimated reading time: < 1 min


Diffuse Large B-cell Lymphoma|Follicular Lymphoma|Malignant Rhabdoid Tumors (MRT)|Rhabdoid Tumors of the Kidney (RTK)|Atypical Teratoid Rhabdoid Tumors (ATRT)|Synovial Sarcoma|Epitheliod Sarcoma|Mesothelioma|Advanced Solid Tumors

Estimated Enrollment: 300

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: EZH-501

Study First Received: August 5, 2016

Last Updated: September 13, 2016

Estimated Primary Completion Date: December 2023

Primary Outcome Measures:

Long-term safety profile of tazemetostat measured by number of AEs and duration of exposure to tazemetostat|The overall survival (OS)

Sponsors and Collaborators:

Epizyme, Inc.

Result Received: No Study Results Posted

Website Link: https://ClinicalTrials.gov/show/NCT02875548

Was this article helpful?
Views: 7